Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Sara M Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data with antibody-drug conjugates in the management of breast cancer.

CME information and select publications here.

Dr Angela DeMichele from the Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Seth Wander from Massachusetts General Hospital in Boston discuss real-world cases and recent clinical data surrounding the management of HR-positive breast cancer.

CME information and select publications here.

Prof Giuseppe Curigliano from the University of Milan in Italy, Prof Nadia Harbeck from LMU University Hospital in Munich, Germany, Dr Ian E Krop from Yale Cancer Center, Dr Nancy U Lin from Dana-Farber Cancer Institute and Dr Joyce O’Shaughnessy from Baylor University Medical Center discuss real-world cases and recent clinical data pertinent to the management of HER2-positive breast cancer.

CME information and select publications here.

Dr Javier Cortés from the International Breast Cancer Center in Barcelona, Spain, Dr Rita Nanda from the University of Chicago, Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood discuss key clinical data with antibody-drug conjugates for metastatic breast cancer and their expert perspectives surrounding its clinical applications.

CME information and select publications here.

Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from The University of Chicago in Illinois engage in an evidence-based discussion around real-world cases involving common toxicities associated with antibody-drug conjugates in the management of breast cancer.

CME information and select publications here.

Prof Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss the implications of clinical findings in breast cancer recently presented at the 2025 ESMO Annual Meeting. 

CME information and select publications here.

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.

Dr Rinath M Jeselsohn and Dr Joyce O’Shaughnessy review current literature and datasets exploring the use of oral selective estrogen receptor degraders for the management of metastatic breast cancer. 

CME information and select publications here.

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.